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Introduction
Aspergillosis is a disease caused by fungi of the genus 
Aspergillus principally A. fumigatus, and less commonly A. 
flavus, A. terreus, and A. niger. The name Aspergillus is derived 
from its resemblance to the sporulating head of Aspergillus and 
the aspergillum/aspergill used to sprinkle holy water (from latin 
aspergere: to sprinkle.) Aspergilli are filamentous saprophytic 
molds ubiquitous in nature that grow in soil, decaying 
vegetation, and water. Direct examination of Aspergillus within 
tissue reveals septated hyphae which dichotomously branch at 
45° as shown in Figure 1.
While Aspergillus can involve a variety of organ systems, 
including the respiratory (lung, sinuses), central nervous, ocular, 
gastrointestinal/hepatic and renal systems causing significant 
morbidity and mortality [1, 2]. This review of literature will focus 
on the pulmonary manifestations of Aspergillus infections. 
Aspergillus causes a spectrum of pulmonary diseases (presented 
in Table 1) determined by the interplay between the pathogen 
Aspergillus, underlying lung disease and the host immunity 
[3-7]. On one end of the spectrum, invasive pulmonary 
aspergillosis (IPA) predominantly affects patients with severe 
immune dysfunction, while chronic pulmonary aspergillosis 
(CPA) affects patients with underlying lung disease but with 
an absence of, or mild immune dysfunction. Acute community-
acquired Aspergillus pneumonia occurs in patients without 
significant immune deficits and normal lungs. Aspergillus 
bronchitis is a chronic bronchitis that is mostly seen in non-
immunocompromised patients with bronchiectasis or cystic 
fibrosis. Allergic bronchopulmonary aspergillosis is due to an 
allergic response to inhaled Aspergillus in asthmatics.
Invasive Pulmonary Aspergillosis 
Acute invasive pulmonary aspergillosis (IPA) is a rapidly 
progressive infection that occurs in highly immunocompromised 
patients and carries a mortality upwards of 50 to 80%. [8, 9] 
The classic risk factor for IPA is neutropenia and the likelihood 
of IPA depends on the duration and severity of neutropenia. 
Histologically, IPA in neutropenic hosts shows angioinvasion 
(Figure 2), while IPA in non-neutropenic patients does not 
usually demonstrate angioinvasion and occurs in a wide range of 
conditions: allogeneic hematopoietic stem-cell transplantation 
after neutrophil recovery, solid organ transplantation, advanced 
AIDS, chronic granulomatous disease, and critically-ill ICU 
patients [10]. The most common risk factors for these patients is 
the use of chronic corticosteroid therapy.
IPA has been increasingly diagnosed in non-neutropenic ICU 
patients who have non-specific risk factors such as sepsis, 
chronic obstructive pulmonary disease (COPD), steroid therapy, 
multiple antibiotic treatments, and hepatic and/or renal failure. 
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Sepsis probably causes a state of ‘immunoparalysis’ and steroids 
cause an immunodeficient state that promotes the occurrence 
of IPA.
The diagnosis of IPA is based on the criteria mentioned in Table 
2. Histopathologic visualization of fungal elements alone is not 
sensitive enough to diagnose invasive aspergillosis and should 
be accompanied by immunostains, cultures and where available, 
nucleic acid amplification tests (NAAT) [11, 12[. Assays for 
PCR and NAAT are not commercially available yet and require 
submission of samples to research or reference laboratories 
that have validated assays. The galactomannan assay is a 
fairly specific and sensitive test for the diagnosis of invasive 
pulmonary aspergillosis. Galactomannan is found in the cell 
wall of Aspergillus species and the assay can be performed in 
serum, BAL and pleural fluid, although the sensitivity is higher 
when performed in BAL fluid than in serum. Galactomannan 
assay results are always used in combination with culture and 
histopathology results. The sensitivity of the assay increases 
with repeated testing (one week apart) and has the highest 
sensitivity among patients with hematological malignancies or 
post-hematopoietic stem cell transplantation [13]. 
False positive serum and BAL galactomannan assays can be 
caused by several beta-lactam antibiotics including piperacillin-
tazobactam and carbapenem [14]. Galactomannan is also found 
in the cell walls of histoplasma capsulatum and fusarium 
spp. The concurrent use of caspofungin has been associated 
with a higher sensitivity of the galactomannan assay likely 
due to the increase in galactomannan levels released from cell 
wall breakdown. In addition to the galactomannan, serum 1,3 
beta-D-glucan test may be helpful, keeping in mind the cross-
reactivity with pseudomonas can yield false positive results [13].
Treatment of IPA
Voriconazole is the recommended primary therapy for IPA 
based on a randomized trial that compared voriconazole with 
amphotericin B deoxycholate and showed improved survival 
with voriconazole [16]. Voriconazole can be given intravenously 
or orally. Alternative primary therapies are liposomal 
amphotericin B and isavuconazonium. Recently, the FDA has 
approved isavuconazonium (a pro-drug of isavuconazole) for 
intravenous and oral treatment of IPA[17]. The recommendation 
was based on a randomized trial of isavuconazonium vs 
voriconazole. All-cause mortality and overall response rates 
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Table 1. Spectrum of Diseases Caused by Aspergillus adapted from Denning et al [3]. (HSCT = Hematopoietic stem-cell transplant; CGD = Chronic 
granulomatous disease).
Aspergillosis syndromes Immune Status Underlying Lung Disease 
Invasive Pulmonary Aspergillosis (IPA) Immunocompromised host 




HSCT recipient, solid organ 
transplant, CGD 
None 
Tracheobronchial Aspergillosis (TBA) Immunocompromised host 
 (AIDS, post-transplant) 
Lung transplant 
Chronic Pulmonary Aspergillosis (CPA) 
Chronic cavitary CPA, fibrosing CPA, 
aspergilloma, and nodule(s) 
Non-immunocompromised host Emphysema, previous 
cavitary tuberculosis 
Aspergillus bronchitis Non-immunocompromised host Bronchiectasis 
Acute Community-Acquired Aspergillus 
Pneumonia 
Non-immunocompromised host Normal lungs/post-influenza 
Allergic Bronchoulmonary Aspergillosis 
(ABPA) 
Non-immunocompromised host 
Hypersensitivity to Aspergillus 
Asthma, cystic fibrosis 
 
Figure 2. A photomicrograph of lung tissue on autopsy showing 
angioinvasion by Aspergillus on H&E stain.
Figure 1. A photomicrograph of lung tissue on autopsy showing 
Aspergillus hyphae with acute angle branching on H&E stain.
were similar in both groups.
Patients who do not respond to monotherapy are considered for 
combination antifungal therapy usually with an echinocandin 
in addition to voriconazole or liposomal amphotericin B. 
The treatment of IPA should be continued for a minimum 
of 6 to 12 weeks, dependent on the duration and severity of 
immunosuppression and the clinical response to therapy [18]. 
Tracheobronchial Aspergillosis (TBA) 
Tracheobronchial aspergillosis is a unique feature of IPA, 
representing isolated tracheobronchial invasion. Predisposing 
factors for TBA are similar to those for IPA, however it has 
been mainly described in lung transplantation recipients, and 
patients with AIDS. The diagnosis requires bronchoscopy. TBA 
has been classified into 3 forms (19). Obstructive TBA manifests 
as thick mucus plugs loaded with Aspergillus spp. without 
obvious bronchial inflammation. Pseudomembranous TBA is 
characterized by extensive involvement of the tracheobronchial 
tree with a membranous slough overlying the mucosa containing 
Aspergillus as shown in Figure 3. 
Ulcerative TBA is a focal process usually found at the suture 
line of the tracheobronchial anastomosis in lung transplant 
recipients. The diagnosis of TBA is usually made by the 
characteristic findings on bronchoscopy (Figure 4) combined 
with microbiological and pathological analysis of the respiratory 
specimens obtained during bronchoscopy.
Treatment of TBA
Similar to IPA, voriconazole or lipid formulation of amphotericin 
B is used. Bronchoscopic debridement of airway lesions and 
minimization of immunosuppression when feasible are also 
considered [20]. In lung transplant recipients with anastomotic 
TBA, adjunctive inhaled amphotericin B is recommended. The 
duration of antifungal therapy is at least 3 months, or until TBA 
has completely resolved.
Neutropenic Fever in Patients with Cancer
Neutropenic patients can be classified as high-risk or low-risk 
[21]. Patients with any of the following are considered high-risk 
if they have:
a. profound neutropenia (ANC < 100 cells/m3), anticipated 
to be prolonged (> 7 days), and 
b. the presence of medical comorbidities: hemodynamic 
instability, oral mucositis causing dysphagia, 
gastrointestinal symptoms (abdominal pain, nausea, 
vomiting or diarrhea), new-onset neurologic changes, 
pneumonia, intravascular catheter infections [21].
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Table 2. Diagnostic criteria for invasive pulmonary aspergillosis per the European Organization for the Research and Treatment of Cancer (EORTC) and 
the Mycosis Study Group [15].
Proven Invasive Pulmonary 
Aspergillosis 
Probable Invasive Pulmonary Aspergillosis Possible Invasive Pulmonary 
Aspergillosis 
¥ Sterile biopsy showing hyphae 
branching at 45° (morphologically 
suggestive of Aspergillus) with 
evidence of associated tissue 
damage 
OR 
¥ Aspergillus on culture of lung biopsy 
specimens 
Clinical criteria (one of the following): 
¥ Recent history of neutropenia (absolute 
neutrophil count < 500 cells) 
¥ Allogeneic stem-cell transplant recipient 
¥ Prolonged corticosteroid exposure (mean 
dose > 0/3mg/kg/day of prednisone 
equivalent for 13 weeks) 
¥ Therapy with known T-cell 
immunosuppressive agents (e.g. 
Cyclosporine, tacrolimus, etc.) 
¥ Hereditary severe immunodeficiency 
AND 
Radiologic criteria on CT (one of the 
following): 
¥ Well-circumscribed, dense lesions ± halo 
sign 
¥ Air-crescent sign 
¥ Cavitary lesion 
AND 
Mycological criteria (one of the following): 
¥ Cytology, culture or microscopy of 
respiratory sample (BAL, bronchial brush) 
showing fungal elements or growing 
Aspergillus 
¥ Detection of antigen or cell-wall 
components (e.g. Galactomannan in 
serum, plasma or BAL) 
Clinical criteria (one of the following): 
¥ Recent history of neutropenia 
(absolute neutrophil count < 500 cells) 
¥ Allogeneic stem-cell transplant 
recipient 
¥ Prolonged corticosteroid exposure 
(mean dose > 0/3mg/kg/day of 
prednisone equivalent for 13 weeks) 
¥ Therapy with known T-cell 
immunosuppressive agents (e.g. 
Cyclosporine, tacrolimus, etc.) 
¥ Hereditary severe immunodeficiency 
AND 
Radiologic criteria on CT (one of the 
following): 
¥ Well-circumscribed, dense lesions ± 
halo sign 
¥ Air-crescent sign 
¥ Cavitary lesion 
 
(Serial testing of beta-D-glucan and 
galactomannan may improve sensitivity 
and specificity) 
 
Figure 3. Pseudomembranous tracheobronchial aspergillosis in an 
immunocompromised patient. a: A cross-section of the trachea at the level 
of the carina showing pseudomembranous tracheobronchial aspergillosis. 
b: Photomicrograph at low-power showing the pseudomembrane of the 
same patient on H&E stain. c: High-power photomicrograph displaying 
Aspergillus hyphae in the pseudomembrane on H&E stain.
High-risk patients who have received intensive cytotoxic 
chemotherapy are at risk for “invasive” fungal infections; yeasts 
(primarily Candida species) and molds (primarily Aspergillus). 
They typically cause persistent or recurrent fever in patients 
with profound (≤ 100 cells/mm3) and prolonged (> 10-15 days) 
neutropenia. Fever may be the only sign in the early stages of 
fungal infections.
The Infectious Diseases Society of America (IDSA) recommends 
empiric antifungal therapy for high-risk neutropenia in patients 
with persistent or recurrent fever after 4-7 days of empirical 
broad spectrum antibiotic therapy [21].
Chronic Pulmonary Aspergillosis (CPA)
There are a multitude of chronic forms of CPA that may overlap 
as illustrated in Figure 5. The progression of CPA is slow 
with a duration of at least 3 months. It affects patients with 
underlying chronic lung conditions, namely tuberculous and 
non-tuberculous mycobacterial infections, COPD, bullous lung 
disease, ABPA, asthma, pulmonary fibrocystic sarcoidosis, lung 
radiation, rheumatoid arthritis, and ankylosing spondylitis [3]. 
The key diagnostic test for CPA is the detection of IgG to 
Aspergillus (or the less sensitive serum Aspergillus precipitins). 
Positive anti-Aspergillus antibodies differentiate infected 
patients from colonized patients, with a positive predictive value 
of 100% for infection. Positive PCR, culture of Aspergillus, or 
galactomannan in respiratory samples provide supportive 
evidence. The diagnostic criteria for CPA are outlined in Figure 
6. 
The most common form of CPA is chronic cavitary pulmonary 
aspergillosis which occurs in non-immunocompromised 
patients with lung disease. When untreated, it may progress to 
chronic fibrosing pulmonary aspergillosis as shown in Figure 
7. Less common forms of CPA are Aspergillus nodule(s) and 
single aspergilloma shown in Figure 8.
Sub-acute invasive aspergillosis also known as chronic 
necrotizing pulmonary aspergillosis. It develops over 4-12 
weeks, usually affects mildly immunocompromised patients 
and manifests with variable radiological features including 
cavitation, nodules, progressive consolidation with ‘abscess 
formation’.
30ULJRI Vol 2, (2) 2018
Clinical Criteria: 
¥ Chronic pulmonary or systemic symptoms (duration > 
3 months) including at least one of the following 
symptoms: weight loss, productive cough or 
hemoptysis. 
¥ No overt immunocompromised conditions (e.g. 
hematological malignancy, neutropenia, organ 
transplantation, chronic granulomatous disease) 
AND 
Radiological Criteria: 
¥ Cavitary pulmonary lesions with evidence of para-
cavitary infiltrates, new cavitary formation, or 
expansion of cavitary size over time. 
AND 
Laboratory Criteria: 
¥ Either positive result of serum precipitins or IgG to 
Aspergillus or isolation of Aspergillus species from 
pulmonary or pleural cavity. 
¥ Elevated levels of inflammatory markers (C-reactive 
protein, erythrocyte sedimentation rate). 
¥ Exclusion of other pulmonary pathogens, by results of 
appropriate cultures and serological tests, that are 
associated with similar disease presentation, 
including mycobacteria and endemic fungi. 
 
Figure 6. An outline of the diagnostic criteria as by Denning et al [23]. All 
criteria must be met to diagnose chronic pulmonary aspergillosis.
Figure 5. A schematic to illustrate the different forms of chronic pulmonary 
aspergillosis, in particular the overlap that is often seen – reproduced from 
Denning et al with permission [22].
Figure 4. Bronchoscopic view of the carina showing the 
appearance of ulcerative tracheobronchial aspergillosis in a 
lung transplant recipient.
Treatment of CPA
1. Treatment of chronic cavitary and fibrosing aspergillosis
Patients with CPA and with pulmonary symptoms 
including progressive loss of lung function or radiographic 
progression should be treated with a minimum of 6 
months of antifungal therapy [18]. Oral Itraconazole and 
voriconazole are the preferred oral antifungal agents; 
posaconazole is an alternative therapy for those with 
adverse effects or clinical failure. Patients with subacute 
invasive aspergillosis should be managed as invasive 
aspergillosis.
2. Treatment of simple aspergilloma
Surgical resection is a definitive treatment for patients with 
adequate pulmonary function.  Intracavitary instillation 
of amphotericin B is an effective short-term treatment 
to control severe hemoptysis [24].  Mild to moderate 
hemoptysis can be controlled with tranexamic acid that 
inhibits fibrinolysis of clots. Catheter embolization of 
the bronchial arteries may be a lifesaving procedure for 
severe hemoptysis, either as a temporizing measure before 
surgery or as a definitive treatment.  
3. Treatment of Aspergillus nodule
A single Aspergillus nodule that has been completely 
excised does not need antifungal treatment if the patient 
is immunocompetent. In immunocompromised patients, 
an oral azole such as oral itraconazole is indicated [3].  In 
a patient with multiple nodules who undergoes surgical 
excision of a single nodule, azole therapy is recommended 
and these patients require radiographic follow up with 
chest CT after excision of a single nodule.  If the residual 
nodules are progressive, continued azole therapy is 
indicated and a repeat biopsy should be considered to rule 
out other etiologies [22].
Acute Community-Acquired Aspergillus Pneumonia
There appear to be 3 different presentations of community 
acquired Aspergillus pneumonia: 
1. massive exposures to airborne Aspergillus spores that 
overwhelm the immunity of the lung to fight infection 
(‘mulch pneumonitis’)
2. lower levels of exposure following influenza infection
3. patients with COPD and those on chronic systemic 
corticosteroid therapy
Chest imaging shows a diffuse miliary pattern in cases of 
massive exposure, or unilateral upper-lobe cavitary disease. 
Aspergillosis may occur in the setting of severe influenza 
infections even among immunocompetent hosts and carries a 
mortality rate of almost 50% [25].  Diagnosis requires a high 
level of suspicion.  Aspergillus can be isolated from optimal 
respiratory tract specimens (bronchoalveolar lavage and 
bronchial brushings) and galactomannan should be detectable 
in the bronchoalveolar lavage (BAL) fluid. 
Prompt therapy with voriconazole is recommended given the 
high mortality rates [26]. 
Aspergillus bronchitis
Aspergillus bronchitis is a chronic superficial Aspergillus 
infection of the bronchial tree in a non-immunocompromised 
patient, usually with bronchiectasis or cystic fibrosis.  If 
the patient has significant immunocompromise (recent 
chemotherapy, transplantation, or AIDS) the term IA 
tracheobronchitis should be applied.  Dr. Denning’s group 
proposed the following criteria for the diagnosis of chronic 
Aspergillus bronchitis [27].
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Figure 8. Single aspergilloma (fungal ball) inside a chronic tuberculous 
cavity overlapping with subacute invasive aspergillosis.
Figure 7. Radiographic appearance of fibrosing CPA on axial (a) CT 
images with coronal (b) reconstruction showing extensive parenchymal 
destruction with cavitation, bronchiectasis and an aspergilloma in the 
right-upper lobe.
Essential criteria
1. Microbiology: Demonstration of Aspergillus in the 
airways at least twice (sputum culture or PCR positive for 
Aspergillus)
2. Chronic (>4 weeks) pulmonary symptoms: Chronic 
productive cough, tenacious mucus production, recurrent 
bronchitis exacerbations with poor response to antibiotics 
and possible systemic symptoms.
3. No significant immune system deficiency.
 
Supportive Criteria
4. Serology: Aspergillus antibody detectable in serum.
5. Bronchoscopy findings: Thick tenacious mucus with 
bronchial plugging, bronchial erythema, or ulceration. 
Superficial invasion of mucosa by Aspergillus hyphae.
6. Response to therapy: Good response to an eight-week 
course of antifungal therapy.
Treatment of Aspergillus bronchitis
Oral azole therapy (itraconazole, voriconazole, posaconazole) 
for 4 months is effective in the majority of patients, however, 
relapse risk is about 50% and these patients may need long-term 
therapy [27].
Allergic Bronchopulmonary Aspergillosis 
ABPA is a pulmonary disorder caused by hypersensitivity to 
Aspergillus fumigatus that complicates the course of patients 
with asthma and cystic fibrosis. It presents with different 
clinical and radiological manifestations such as refractory 
asthma, recurrent fleeting pulmonary infiltrates with or without 
bronchiectasis. ABPA should be suspected in all patients with 
asthma and cystic fibrosis regardless of the severity or the level 
of disease control. A working group of ‘ABPA in asthmatics’ 
formed by the International Society of Human and Animal 
Mycology (ISHAM) convened an expert group that proposed 
new criteria for ABPA in 2013 [28]. Subsequently, Agarwal 
et al have recently proposed new criteria outlined in Table 3 
[29]. Comparing the ABPA working group criteria to the criteria 
proposed by Agarwal et al, the proposed criteria include a larger 
array of lung disease (COPD, post-tuberculous fibrocavitary 
disease) and identifies a specific A. fumigatus IgG level. The 
diagnostic algorithm for ABPA is outlined in Figure 9.
Treatment of ABPA
ABPA has distinct stages of progression from an acute infection 
(stage 1) to advanced ABPA (stage 6) as listed in Table 4. The 
treatment of ABPA has been described by Agarwal et al [29], 
highlighted in the flowchart shown in Figure 10. Primary 
treatment of ABPA involves corticosteroids for asthma attacks 
associated with ABPA. The most frequently used schedule is 
the low-dose steroid regimen (prednisone 0.5mg/kg/day) for 
2 weeks followed by 0.5/mg/kg every other day for 8 weeks, 
then tapered by 5mg every 2 weeks for a total duration of 3 to 
5 months. Alternative treatments describe oral Itraconazole 
200mg twice daily for 16 weeks or longer. Itraconazole has 
been shown to decrease the number of exacerbations requiring 
steroids with improved lung function and exercise tolerance. 
[30, 31] Itraconazole can eliminate Aspergillus in the airways 
and can theoretically reduce the allergic responses in ABPA. 
The aim of the MIPA trial (Monotherapy of Itraconazole Versus 
Prednisolone in Allergic Bronchopulmonary Aspergillosis; 
clinicaltrials.gov ID: NCT01321827), a prospective randomized 
controlled trial that is currently underway, is to evaluate the 
efficacy and safety of itraconazole monotherapy in patients with 
ABPA. 
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Bronchial asthma 
Total IgE > 500 IU/mL 
Eosinophil count > 500 cells/µL 
Aspergillus fumigatus IgG > 27 mgA/L 
High-resolution chest CT 






Aspergillus fumigatus specific IgE levels > 0.35 
kUA/L 
Figure 9. Suggested protocol for the diagnosis of allergic 
bronchopulmonary aspergillosis (ABPA) adapted from Agarwal et al [29].
Table 3.  A table comparing the diagnostic criteria for ABPA by the ABPA Working Group and those proposed by Agarwal et al [29]. (COPD: chronic 
obstructive pulmonary disease; kUA: kilounit of antibody; mgA: milligram of antibody; ABPA: Allergic bronchopulmonary Aspergillosis; Ig: immunoglobulin.)
ABPA Working Group Criteria Criteria Proposed by Agarwal et al 
Predisposing conditions: 
 Bronchial asthma and cystic fibrosis 
Predisposing conditions: 
 Bronchial asthma, cystic fibrosis, COPD, post-tuberculous fibrocavitary disease 
Essential criteria: 
 Serum A. fumigatus specific IgE levels > 0.35 kUA/L 
or positive type I Aspergillus skin test 
AND 
 Elevated serum total IgE levels > 1000 IU/ml (an IgE 
value <1000 IU/ml may be acceptable if all other 
criteria are met, especially if the serum A. 
fumigatus specific IgG level > 27 mgA/L). 
Essential criteria: 
 Serum A. fumigatus specific IgE levels > 0.35 kUA/L (a positive type I Aspergillus skin test 
may be considered as a criterion in place of serum A. fumigatus specific IgE levels only if 
the latter test is not available) 
AND 
 Elevated serum total IgE levels > 1000 IU/ml (an IgE value <1000 IU/ml may be acceptable 
if all other criteria are met, especially if the serum A. fumigatus specific IgG level >27 
mgA/L). 
Additional criteria (two of three must be met): 
 Presence of precipitating (or IgG) antibodies against 
A. fumigatus in serum 
OR 
 Thoracic imaging findings consistent with ABPA 
o Transient abnormalities: nodules, consolidation, 
mucoid impaction, hyper-attenuating mucus, 
fleeting opacities, toothpaste/gloved-finger 
opacities, or tram-track sign 
o Permanent abnormalities: parallel lines, ring 
shadows, bronchiectasis, pleuropulmonary 
fibrosis 
OR 
 Historical or current peripheral blood eosinophil 
count > 500 cells/µL. 
Additional criteria (two of three must be met): 
 Serum A. fumigatus IgG level > 27 mgA/L 
OR 
 Thoracic imaging findings consistent with ABPA 
o Transient abnormalities: nodules, consolidation, mucoid impaction, hyper-attenuating 
mucus, fleeting opacities, toothpaste/gloved-finger opacities 
o Permanent abnormalities: parallel lines, ring shadows, bronchiectasis, 
pleuropulmonary fibrosis 
OR 
 Historical or current peripheral blood eosinophil count > 500 cells/µL. 
 
Conclusions
The different clinical syndromes caused by Aspergillus can be 
considered as a continuous spectrum of disease resulting from 
the interplay of Aspergillus, host immunity and underlying 
lung disease. The spectrum runs from invasive pulmonary 
aspergillosis to Aspergillus bronchitis. One form of aspergillosis 
may evolve from one form into another depending of the degree 
of immunity of the host. Prompt diagnosis and treatment with 
appropriate antifungals are essential for improved outcomes.
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Table 4.  The treatment stages of ABPA adapted from Agarwal et al [29].
Figure 10.  A flowchart illustrating the treatment and response algorithm 
adapted from Agarwal et al [29].
Stage Definition Features 
0 Asymptomatic No previous diagnosis of ABPA 
Fulfills criteria for ABPA 
Controlled asthma per GINA guidelines 
1 Acute ABPA No previous diagnosis of ABPA 
Fulfills criteria for ABPA 
Uncontrolled asthma or symptoms consistent with ABPA 
2 Response Clinical and/or radiographic improvement  
AND 
Decline in IgE ≥ 25% of baseline at 8 weeks 
3 Exacerbation Clinical and/or radiographic worsening 
AND 
Increase in IgE ≥ 50% from baseline established during response/remission 
4 Remission Sustained clinical and radiographic improvement 
AND 
IgE levels persisting at or below baseline (or increase by < 50) for ≥ 6 months off treatment 
5 Treatment-
dependent 
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